Medicus advances Teverelix and SkinJect programs with key regulatory filings

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to discuss two significant regulatory milestones that advance the company’s pipeline in women’s health and rare disease oncology. The company has submitted an Investigational New Drug (IND) application to the Department of Health – Abu Dhabi for PRECISION-E2, a first-of-its-kind Phase 2a genomics-enabled clinical trial evaluating Teverelix® in women with symptomatic endometriosis. The randomized, placebo-controlled study is expected to enroll approximately 84 women across multiple sites in the UAE and will leverage participants from the Emirati Genome Program, one of the world’s largest national genomics initiatives. The trial is designed to combine clinical outcomes, hormonal biomarkers, pharmacokinetic and pharmacodynamic data, and genomic analysis to better understand treatment response variability. Researchers will evaluate three Teverelix treatment regimens with the goal of identifying the optimal dose an...